

REFERENCES

1. **BraunwaldE,Antman EM , Beasey TW, Hochman JS et al .** American college of cardiology, American heart association comment on management of patients with unstable angina J.A.M collcardiol 2002 .
2. **BonoraE,TargherG,FormentiniG, et al .** he metabolic syndrome is an independent predictor of cardiovascular disease in type II DM. prospective data from Verona diabetes complication study. diabetes MED 2004 .
3. **Ford ES :**the metabolic syndrome and mortality from cardiovascular disease and all causes : findings from national health and nutrition examination survey II mortality study. atherosclerosis 2004.
4. **SolymossBC, BourasaMG, Sinderman A et al .** Effect of increasing metabolic syndrome on coronary artery disease angiographic severity Am J cardiol 2004.
5. **AHA Nutrition Committee Eckel RH, Krauss RM et al.** American Heart Association call to action: obesity as a major risk factor for coronary heart disease. Circulation. 1998;97:2099–2100.
6. **Garrison RJ, Higgins MW, Kannel WB et al.** Obesity and coronary heart disease. CurrOpinLipidol. 1996;

✍ References

7. **Garrison RJ, Castelli WP et al** . Weight and thirty-year mortality of men in the Framingham study. Ann Intern Med. 1985.
8. **Ellis SG, Elliot J, Horrigan M, Raymond RE, Howell G et al**. newly identified and powerful risk factors for death and other complications with percutaneous coronary intervention. Am J Cardiol. 1996.
9. **Medline plus metabolic syndrome**
10. **Ford ES, Giles WH, Dietz WH et al (2002)**. Prevalence of metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.
11. **NAustralia (February 12-13, 1998), Dr Allen E. Gale, Consultant Physician (Allergy):** identifies the acronym CHAOS as an abbreviation for Coronary artery disease, Hypertension, Atherosclerosis, Obesity, and Stroke.
12. **National Cholesterol Education Program (NCEP)** Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002.
13. **Balkau B, Charles MA, et al**. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999; **Clinical Guidelines on the**

✍ References

- Identification**, Evaluation, and Treatment of Overweight and Obesity in Adults—the Evidence Report. National Institutes of Health. *Obes Res*. 1998; .
14. **International Diabetes Federation. Worldwide definition of the metabolic syndrome.** Available at: [http:](http://) August 24, 2005.
 15. **KD, Clark PC, Grossniklaus DA, Igho-Pemu P, et al (2010).** Metabolic syndrome in African Americans: views on making lifestyle changes.
 16. **Balkau B, Charles MA et al (1999) .** Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR)..
 17. **Cornier MA, 1-Kirkendoll D, Hernandez TL, et al (2008).** The Metabolic Syndrome. *Endocrine Reviews*.
 18. **Mikkola I, Keinänen-Kiukaanniemi S, Laakso M, et al .** Meyer-Rochow VB, Juuti AK, Peitso A, Timonen M. (2007). Metabolic syndrome in connection with BMI in young Finnish male adults.
 19. **Al-Lawati JA, Mohammed AJ, Al-Hinai HQ, et al.** Prevalence of the metabolic syndrome among Omani adults. *Diabetes Care*. 2003.
 20. **Kawamoto R, Kohara K, Tabara Y, et al.** Serum gamma-glutamyltransferase levels are associated with metabolic syndrome in community-dwelling individuals. *J AtherosclerThromb*. 2009.

References

21. **Esteghamati A, Jamali A, Khalilzadeh O, et al.** Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound. 2010.
22. **Kasapoglu B, Turkay C, Bayram Y, et al .** Role of GGT in diagnosis of metabolic syndrome: a clinic-based cross-sectional survey. Indian J Med Res. 2010. -.
23. **Kraja AT, Hunt SC, Pankow JS, et al.** An evaluation of the metabolic syndrome in the HyperGen study. 2005.
24. **Ford ES, Giles WH, Dietz WH, et al.** Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutritional Examination Survey. JAMA. 2002.
25. **Yusuf S, Reddy S, Ounpuu S, et al .** Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2010.
26. **Makuyana D, Gomo Z, Munyombwe T, et al .** Metabolic syndrome disorders in urban black Zimbabweans with type 2 Diabetes mellitus. Cent Afr J Med. 2004.
27. **Ntyintyane LM, Panz VR, Raal FJ, et al .** Metabolic syndrome, undiagnosed diabetes mellitus and insulin resistance are highly prevalent in urbanised South African blacks with coronary artery disease. Cardiovasc J S Afr. 2006.

References

28. **Ker JA, Rheeder P, Van Tonder R.** Frequency of the metabolic syndrome in screened South African corporate executives. *Cardiovasc J S Afr.* 2007.
29. **Santos AC, Barros H.** Impact of metabolic syndrome definitions on prevalence estimates: a study in a Portuguese community. *Diabetes Vasc Dis Res.* 2007.
30. **Hu G, Qiao Q, Tuomilehto J, Balkau B, et al;** DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. *Arch Intern Med.* 2004.
31. **Pollex, R.L.; Hegele, R.A, et al . (2006).** "Genetic determinants of the metabolic syndrome". .
32. **Katzmary k,, Peter T; Arthur S, Jack H, et al . (October 2003).** "Targeting the Metabolic Syndrome with Exercise: Evidence from the HERITAGE Family Study."
33. **"Hypothalamic-pituitary-adrenal axis function and the metabolic syndrome X of obesity".** *CNS Spectr.* , PMID.
34. **Tsigos, C; Chrousos, GP; (October 2002) .** "Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress". *J Psychosom Res,* PMID.
35. **Rosmond, R; Björntorp, et al (February 2000).** "The hypothalamic-pituitary-adrenal axis activity as a predictor of

References

- cardiovascular disease, type 2 diabetes and stroke". J Intern Med. 2002.
36. **Brunner, EJ; Hemingway H; Walker BR , Page M, et al** .(November 2002). "Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome.
37. **Yusuf S , Hawken S , Ounpuu S , Dans T, et al.** INTERHEART Study Investigators. (2004). "Effect of potentially modifiable risk factors associated with myocardial infarction (the INTERHEART study): Case-control study".
38. **International Diabetes Federation.**Worldwide defination of the metabolic syndrome August 24,2005.
39. **Fauci, Anthony S. (2008).**Harrison's principles of internal medicine.
40. **World Health Organisation Department of Noncommunicable Disease Surveillan"**Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications.
41. **<http://www.diabetes.co.uk/diabetes-and-metabolic-syndrome.html>** Diabetes and Metabolics.
42. **Lara-Castro C, Fu Y, Chung BH, et al (June 2007).** "Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease". .
43. **Renaldi O, Pramono B, Sinorita H, Purnomo LB, et al** .(January 2009). "Hypoadiponectinemia: a risk factor for metabolic syndrome".

References

44. **Lowe HC, Oesterle SN , Khachigian LM,et al** .Coronary in-stent restenosis : current status and future strategies. J Am CollCardiol 2002.
45. **Janket SJ, Manson JE, Sesso H, Liu S, et al** . A prospective study of sugar intake and risk of type 2 diabetes in women. Diabetes Care. 2003 Apr.
46. **Pham, T; Cornea A; Blick KE; Jenkins A, et al (2007).**"Oral Glucosamine in Doses Used to Treat Osteoarthritis Worsens Insulin Resistance". The American Journal of the Medical Science.
47. **Jeff Unger.** "Intensive Management of Type 2 Diabetes". EmergencyMedicine.
48. **Hoehn KL, Salmon AB, Hohnen-Behrens C, et al (2009).** Insulin resistance is a cellular antioxidant defense mechanism.
49. **Kerry-Lee M, David P, Michael T, Arthur B. , George J, et al** . Chisholm Chronic Hepatitis C is Associated with Peripheral Rather Than Hepatic Insulin Resistance
50. **Boden G, Sargrad K, Homko C, Mozzoli M, et al (2005).**"Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes".
51. **Bramnert M, Segerlantz M, Laurila E, Daugaard JR, et al** .**(2003).**"Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle".

✍ References

52. **Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, et al** .Diabetes Prevention Program Research Group (2002). "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin". New England Journal of Medicine..
53. **Newsom, S.; Schenk, S.; Thomas, K.; Harber, M.; Goldenberg, N.; et al (2009).** "Energy deficit after exercise augments lipid mobilization but does not contribute to the exercise-induced increase in insulin sensitivity."
54. **Judith R, Monamara, G. Russell W, Lily L, et al(2000).** Lipid and lipoproteins. Clinical Chemistry 4th edition 2000.
55. **Jackson RL, McLean LR, Ponce E, et al, (1987).** Mechanism of action on lipoproteins and hepatic triglyceride lipase.
56. **De Franzo RA, Feramini E,et al (1991).** Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease.
57. **Chait A, Robertson HT, Brun Zell TD, et al 1981.**Chylomicronemia syndrome in diabetes mellitus. Diabetes Care,
58. **Frayn KN, 1993.** Insulin resistance and lipid metabolism.

References

59. **Chu JW, Abbasi F, Kulkarni KR, Lamendol C, et al., 2003.** Multiple lipoprotein abnormalities associated with insulin resistance in healthy volunteers.
60. **Zeljko Reiner, 2000.** Pathophysiology and classification of cardiovascular disease caused by atherosclerosis. JIFCC..
61. **Ross R, 1999.** Atherosclerosis is an inflammatory disease.
62. **Sharrett AR, Patsch W, Sorlie PD, et al., 1994.** Associations of lipoprotein cholesterol, apolipoprotein A-1 and B, and triglycerides with carotid atherosclerosis and coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study.
63. **Garrison Somer E, 1995.** The Nutrition Desk Reference 3rd Eds.
64. **Navab M, Berliner JA, Watson AD, et al .,(1996).** the yin and yang of oxidation in the development of fatty streak.
65. **Barter PJ, 1997.** Inhibition of endothelial cell adhesion molecular expression by high-density lipoproteins.
66. **Nilsson J, Dahlgren B, Ares M, et al.,(1998).** Lipoprotein-like phospholipid particles inhibit the smooth muscle cell cytotoxicity of lysophosphatidylcholine and platelet activating factor.
67. **Zeier AM, Schachlinger V, Hohnloser SH, et al.,(1994).** Coronary atherosclerotic wall thickening and vascular reactivity in humans: elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation.

✍ References

68. **Griffin JH, Kojima K, Banka CL, et al,(1999).** High-density lipoprotein enhancement of anticoagulant activities of plasma proteins and activated protein C.
69. **Williams KJ and Tabas I, et al (1998).** The response to retention hypothesis of atherogenesis reinforced.
70. **Vasan RS, Beiser A, Sehard S, et al.(, 2002).** Residual lifetime risk for developing hypertension inmiddle aged women and men. The Framingham Heart Study. .
71. **Cherry DK and Woodwell DA , et al (2002).** National Ambulatory Medical Care Survey, 2000.
72. **NIH publications, 1997.** The sixth report of the Jiont National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.
73. **Lewington S, Clarke R, Qizilbosk N, et al.,(2002).** Age specific relevance of ususal blood pressure to vascular mortality. A meta-analysis of individual data for one million adults in prospective studies.
74. **Fuster V and Pearson TA, et al (1996).** Matching the intensity of risk factors management with the hazard of coronary disease events. .
75. **Pouliot MC, Despres JP, Lemieux S, et al.,(1994).** Waist circumference and abdominal sagittal diameter: best simple

References

- anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women.
76. **Reaven GM, Lithell H, Landsberg L, et al (1996).** Hypertension and associated metabolic abnormalities, the role of insulin resistance and the sympathoadrenal system.
77. **Gerald M, Reaven GM, Hans L, Lewis Landsberg, et al.(1996).** Hypertension and associated metabolic abnormalities. The role of insulin resistance and the sympathoadrenal system. The New England Journal of Medicine.
78. **Reaven GM, (1991).** Insulin resistance, hyperinsulinemia, hypertriglyceridemia and hypertension: parallels between human disease and rodent models..
79. **Pollare T, Lithell H, Berne C, et al.(1990).** Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism.
80. **Reaven GM, 2000.** Syndrome X: Overcoming the silent killer that can give you a heart attack.
81. **Byron J H, Dennis L S , Gregory L P et al.(2002).** Blood glucose level concentration ≤ 125 mg/dl and coronary heart disease risk.
82. The effect of intensive treatment of diabetes on development and progression of long term complications in insulin-dependent diabetes

References

- mellitus .**The Diabetes Control and complications Trial research Group. Nengl Med .**
83. Joint British recommendations on prevention of coronary heart disease in clinical practice. **British Cardiac Society, British Hyperlipidaemia Association. Heart 1998.**
84. **Richard, C.B ., Joseph, S., Worcester L,et al .** Electrocardiographic ST segment depression in coronary heart disease., **1992.**
85. **Grossman, W. and Baim D, et al .:**Cardiac catheterization, angiography and intervention (5th edition). Philadelphia, **1996.**
86. **Gould, K.L., Schelbert H.R., Phelps M.E and Hoffman E.J , et al.** Noninvasive assessment of coronary stenoses with myocardial perfusion imaging during pharmacologic coronary vasodilatation. .
87. **White C.W., Wright C.B., Doty D.B., Hiratza L.F., et al :** Does visual interpretation of the coronary arteriogram predict the physiologic importance of a coronary stenosis? .
88. **Nesto, R.W., and Kowalchuk, G.J. et al:** The ischemic cascade: temporal sequence of hemodynamic, electrocardiographic and symptomatic expressions of ischemia.
89. **Wijns, W., Serruys P.W., Slager, C.J., Grimm, J. , et al .:** Effect of coronary occlusion during percutaneous transluminal angioplasty in

✍ References

- humans on left ventricular chamber stiffness and regional diastolic pressure-radius relations.1986.
90. **Armstrong, W.F.:** **Echocardiography In: Zipes, D.P., Libby, P., Braunwald E., et al:** A textbook of cardiovascular medicine, Philadelphia, 2005.
 91. **Holmes Jr DR, Teirstein P, Satler L, et al:** Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: The SISR randomized trial. JAMA 2006.
 92. **Stone GW, Lansky AJ, Pocock SJ, et al:** Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction, J Med 2009.
 93. **Williams DO, Abbott JD, Kip KE , et al :** Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: Report of the DEScover Registry. Circulation 2006
 94. **Hannan EL, Wu C, Bennett EV, et al:** Risk index for predicting in-hospital mortality for cardiac valve surgery.,2007.
 95. **Abizaid A, Ran K, Gary M, et al,:** The inflence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am CollCardiol , 1998.
 96. **Singh M, Gersh BJ, Lennon RJ, et al:** Outcomes of a system-wide protocol for elective and nonelective coronary angioplasty at sites without on-site surgery: The Mayo Clinic experience, 2009.

References

97. **Gould KL, Lipscomb K, Hamilton GW , et al.** Physiologic Basis for assessing critical coronary stenosis : instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve.
98. **Mehran R, Dangas G, Abizaid AS, et al.** Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. *Circulation*. 1999.
99. **Kearney M, Ann P, Laura H et al.** Histopathology of in-stent restenosis in patients with peripheral artery disease, *Circulation* 1999 .
100. **Baron JH, Aggawal RK, Azrin MA, et al.** Development of C7E3 (Abciximab) eluting stents for local drug delivery effect of sterilization and storage. *Circulation* , 1998 (abstract).
101. **Garasic JM, Edelman ER, Rogers C, et al '.** Stent and artery geometry determine initial thickening independent of deep arterial injury. *Circulation* , 1997.
102. **Kornowski R, Hong MK, Tio FO, et al;.** ISR. Contributors of inflammatory responses and arterial injury to neo-intimal hyperplasia. *J Am CollCardiol* , 1998.
103. **Kip KE, Faxon DP, Detre KM et al;.** Coronary angio-plasty in diabetic patients: the National Heart, Lung, and Blood Institute

References

- Percutaneous Transluminal Coro-nary Angioplasty Registry. Circulation , 1996.
104. **Carroza JP Jr, Kuntz RE, Fishman RF, et al** ;Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1999.
105. **Kastrati A, Albert S, Shpend E, et al.** Predictive factors for restenosis after coronary stent placement. J Am CollCardiol , 1997.
106. **Kornowski R, Mintz GS, Kent KM, Pichard AD, et al** ;Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia: a serial intravascular ultrasound study. Circulation , 1997.
107. **Andrew K, Ralph S, Clive L, et al** ;. Long stenting in native coronary arteries: Relation between vessel size and outcome. Catheterization and cardiovascular diagnosis , 1998.
108. **Bauters C, Eduard H, Alain P, et al.;** Predictors of restenosis after coronary stent implantation. J Am CollCardiol 1998.(A)
109. **Kobayashi Y, De Gregorio J, Kobayashi N, et al.** Stented segment length an independent predictor of restenosis. Am. Coll. Cardiol , 1999.
110. **Kastrati A, Schomig A, Elezi S, Dirschinger J, Mehilli J, et al,;** Prognostic value of the modified ACC/AHA stenosis morphology

✍ References

- classification for long term angiographic and clinical outcome after coronary stent placement. *Circulation*, 1999.
111. **Aliabadi D, Bowers T, Spybrook M, et al .;**Multiple stents increase target vessel revasculari- zation rates. *J Am CollCardiol* , 1997. (Abstract).
112. **Inoue N, Takaomi T, Akiko M, et al. ;**The infection of chlamydia pneumonia accelerates neointimal hyperplasia associated with instent restenosis. *J Am CollCardiol* , 1999 (Abstract).
113. **Flavio R, Giuseppe S, Antonio D, et al.;** Plasma activity and insertion/deletion polymorphism of angiotensin I converting enzyme a major risk factor and a marker of risk for coronary stent restenosis. *Circulation* , 1998.
114. **Marso SP, Lincoff AM, Ellis SG, et al ;**Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. *Circulation* , 1999.
115. **Bhatt DL, Marso SP, Lincoff AM, et al.;** ;Abciximab reduces mortality in diabetics following percutaneous coronary intervention. *J Am CollCardiol* , 2000.
116. **Steinhubl SR, Berger PB, Mann JT III, et al.;** Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. *JAMA* , 2002.

References

117. **Sebastian M, Hidehiko H, Raj M, et al.;** Local delivery of chimeric DNA: RNA ribozymes targeting PCNA with the Cordis crescendo catheter inhibits in-stent restenosis in a porcine model. J Am CollCardiol (Abstract), 1999.
118. **Balram B, Ganesan K, Alexandre S A, Roxana M, et al.;** New approaches to preventing restenosis., 2003.
119. **Mehran R, Gary M, Jeffery P, et al.:** Mechanisms and results of balloon angioplasty for the treatment of in-stent restenosis. Am J Cardiol , 1996.
120. **Waksman R, Bhargava B, Mintz GS, et al.;** Late total occlusion following intracoronary brachytherapy for patients with in-stent restenosis. J Am CollCardiol 2000.
121. **Koster R, Christian H, Wolfram T, et al.:** Treatment of in-stent coronary restenosis by excimer laser angioplasty. Am J Cardiol , 1997.
122. **Shpend E, Adnan K, Helmut S, et al ;.** Stenting for restenosis for restenosis of stented lesions: Acute and 6-months clinical and angiographic follow-up. Circulation , 1997 (Abrascet).
123. **Bottner R and Kenneth H, et al.;** High speed rotational ablation for in-stent restenosis. Catheteri-zation and cardiovascular diagnosis ,1997.
124. **Gaziano TA and Gaziano JM , et al ;.** Epidemiology of Cardiovascular Disease. In: Fauci AS, Braunwald E, Kasper DL,

References

- Hauser SL, Longo DL, Jameso JL,. Harrison Principals of Internal Medicine.
125. **Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, et al.;**
(2004): Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.Circulation. 2004.
126. **Lu YH, Lu JM, Wang SY, Li CL, Liu LS, Zheng RM, et al.;**
Comparison of the diagnostic criteria of metabolic syndrome by International Diabetes Federation and that Chinese Medical Association Diabetes Branch. Natl Med J Chin (Chin) 2006.
127. **Salvatore M, Kristian B. Filion J G , Lawrence J, Louise P, et al.;**
(2010): The Metabolic Syndrome and Cardiovascular Risk A Systematic Review and Meta-Analysis, J Am CollCardiol, 2010.
128. **HU Rong, MA Chang-sheng, NIE Shao-ping, KANG Jun-ping, et al,;**
. Effect of metabolic syndrome on prognosis and clinical characteristics of revascularization in patients with coronary artery disease. Chinese Medical Journal 2006.
129. **J.S. Rana, P.S. Monraats, J.W. Jukema, M.P. de Maat, et al ,;**
Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary intervention, Daibet. Care ,2005.
130. **Lopes NH, Paulitsch FS, Pereira AC, Gagliardi A, ,et al .** Impact of metabolic syndrome on the outcome of patients with stable

References

- coronary artery disease: 2-year follow-up of the MASS II study. *Coron Artery Dis.* 2008 .
131. **AmjadA, Shimal K, Mahboobur R, Tehmina J, et al;** Angiographic Severity of Coronary Artery Disease in Patients with Metabolic Syndrome. *Gomal Journal of Medical Sciences* July-December 2011..
132. **Vakil K, Malhotra S, Stephen S, Steffanie R. C, et al ;.** Waist Circumference and Metabolic Syndrome: The Risk for Silent Coronary Artery Disease in Males. *Metabolic Syndrome and Related Disorders.* June 2012.
133. **Park yw, zhu, Palamiappanl, H,Carnethon MR, Heymsfield S B, et al;** the metabolic syndrome prevalence and assessed risk Factors,,findindings in the US population from the national health, Nutrition examination survey1988, *internal medicine* 2003
134. **FlagelM, Carroll.D,Ogden C.Let.al (Jaurny2006) .** prevelance and Trends in obesity among US adults (1999 -2008) *JAMA* ..
135. **Alejandra Madrid-Miller, Antonio Alcaraz-Ruiz,et al.** Metabolic syndrome: clinical and angiographic impact on patients with acute coronary syndrome.
136. **BirhanYilmaz M, Guray U, Guray Y, et al.** Metabolic syndrome is associated with extension of coronary artery disease in patients with non-ST segment elevation acute coronary syndromes,2005.

References

137. **Kim J, Han Cheol Lee, Bo-Kyung Choi, et al.**, Impact of metabolic syndrome on in-stent restenosis and clinical outcomes after percutaneous coronary stent implantation.
138. **Mehta SR, Bassand JP, Chrolavicius S, et al:** Design and rationale of CURRENT-OASIS randomized factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
139. **El-Omar M, Dangas G, IakovouI, et al:** Update on In-stent Restenosis. Current Interventional Cardiology Reports 2001.
140. **George, BS, Voorhees, WD, RoubinGS et al.;** Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty: Clinical and angiographic outcomes. J Am CollCardiol 1993.
141. **Montalescot G, Sideris G, Meuleman C, et al:** A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: The ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006.
142. **Centers for Disease Control & Prevention.** Differences in prevalence of obesity among black, white, and Hispanic adults – United States, 2006 – 2008.

References

143. **Barnes P. 2009 National Health Intervie Survey**, Centers for Disease Control & Prevention, National Center for Health Statistics
144. **George, BS, Voorhees, WD, Roubin et al.** Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous coronary angioplasty: Clinical and angiographic outcomes. Am Coll Cardiol 1993..
- 146 **Lima-Filho M, Figueiredo G, Foss-Freitas M et al.** Predictors of restenosis after percutaneous coronary intervention using bare-metal stents. A comparison between patients with and without dysglycemia. June 2010.
145. **Verin V, Popowski Y, de Bruyne B et al.** Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty. The Dose -Finding Study Group, 2001.
146. **HU Rong, MA Chang-sheng, NIE Shao-ping, et al.** Effect of metabolic syndrome on prognosis and clinical characteristics of revascularization in patients with coronary artery disease .
147. **Drozd J , Wójcik J, Małek R, Korona B, Zapolski T, et al.** ACS , as frequent clinical manifestation of BMS instent restenosis.